Teva announces positive Phase III GALA study results
The trial was designed to examine the efficacy, safety and tolerability of glatiramer acetate 40mg/ml injection administered three times a week compared to placebo in over 1,400 patients
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
Adva-27a is Sunshine Biopharma’s lead anti-cancer compound that kills Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR). The pre-IND-Enabling studies include in vitro biological